In a report released on December 28, Ryan Zimmerman from BTIG maintained a Hold rating on Staar Surgical (STAA – Research Report). The company’s shares closed last Friday at $31.21.
Zimmerman covers the Healthcare sector, focusing on stocks such as Glaukos, Vericel, and Stryker. According to TipRanks, Zimmerman has an average return of 8.9% and a 47.46% success rate on recommended stocks.
Staar Surgical has an analyst consensus of Hold, with a price target consensus of $44.80.
See today’s best-performing stocks on TipRanks >>
STAA market cap is currently $1.52B and has a P/E ratio of 79.35.
Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of STAA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Staar Surgical (STAA) Company Description:
STAAR Surgical Co. engages in the development, manufacture, production, marketing, and sale of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It specializes in refractive and cataract solutions. Its products include intraocular lens and implantable collamer lens. The company was founded in 1982 and is headquartered in Lake Forest, CA.
Read More on STAA:
